The FDA approved Zoryve cream 0.05% for the treatment of children aged 2 to 5 years with mild to moderate atopic dermatitis, ...
ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well ...
Ruxolitinib cream was approved for moderate atopic dermatitis in non-immunocompromised patients aged 2 years and older. The phase 3 TRuE-AD3 study showed significant efficacy and safety in children ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback